Hydroxychloroquine in Covid-19: Does the end justify the means?

Curr Res Transl Med. 2020 Aug;68(3):81-82. doi: 10.1016/j.retram.2020.04.002. Epub 2020 Apr 18.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibody Formation / drug effects*
  • Antiviral Agents / therapeutic use
  • Azithromycin / administration & dosage
  • Azithromycin / adverse effects
  • Betacoronavirus / drug effects
  • Betacoronavirus / physiology
  • COVID-19
  • COVID-19 Drug Treatment
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Drug Therapy, Combination / adverse effects
  • Humans
  • Hydroxychloroquine / administration & dosage
  • Hydroxychloroquine / adverse effects*
  • Hydroxychloroquine / pharmacology
  • Immunity, Cellular / drug effects*
  • Immunity, Herd / drug effects*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • SARS-CoV-2
  • Viral Load / drug effects
  • Viral Vaccines / therapeutic use

Substances

  • Antiviral Agents
  • Immunosuppressive Agents
  • Viral Vaccines
  • Hydroxychloroquine
  • Azithromycin